What the labels cover, and what they do not
The US prescribing information for Mounjaro®, a weekly tirzepatide injection for type 2 diabetes, lists no cognitive effects in its tables or postmarketing section [1]. The European product information, which pools 14 phase 3 studies, and the Canadian monograph do not list any either [3][4].
Confusion does appear in a different role. The Medication Guide lists confusion or drowsiness, slurred speech, blurred vision and mood changes among the signs of low blood sugar [2], and the Canadian patient information describes severe low blood sugar as causing disorientation, loss of consciousness or seizure [4]. The labels tie that risk mainly to combining Mounjaro® with insulin or a sulfonylurea [1].
The second documented route is fluid loss. The labels warn that nausea, vomiting and diarrhea can cause dehydration and kidney problems [1][2], and irritability or confusion is among the signs of severe dehydration [10].
What research has found so far
Evidence specific to tirzepatide and everyday thinking is thin. A 2026 analysis of the FDA Adverse Event Reporting System found 144 reporting signals for tirzepatide, including Wernicke’s encephalopathy, a brain disorder caused by lack of thiamine (vitamin B1), which the author linked to low food intake [5]. Reporting signals show what is reported unusually often; they do not prove that the medicine caused it.
A 2026 case report described a 50-year-old man with obesity and long-standing alcohol use disorder who developed severe memory problems within weeks of starting tirzepatide, during rapid weight loss [6]. He was diagnosed with Korsakoff syndrome, and his memory did not fully recover despite thiamine. It is a single case with a strong additional risk factor, so it cannot show how often this happens.
Looking further ahead, a large US health-record study of adults with type 2 diabetes found fewer new diagnoses of mild cognitive impairment after starting tirzepatide than after starting semaglutide [7]. The authors describe the result as hypothesis-generating; it does not measure day-to-day fog and cannot establish cause.
| Evidence | Finding | Limit |
|---|---|---|
| US, EU and Canadian labels | No cognitive side effect listed; confusion listed as a low blood sugar sign [1][2][3][4] | Rare effects can be missed in trials |
| FAERS disproportionality analysis, 2026 | Signal for Wernicke’s encephalopathy [5] | Reports only; no cause or rate |
| Case report, 2026 | Korsakoff syndrome after rapid weight loss in a man with alcohol use disorder [6] | One patient |
| Health-record cohort, 2026 | Fewer mild cognitive impairment diagnoses than with semaglutide [7] | Observational; long-term outcome |
How Mounjaro® could contribute
Supported by the labels: low blood sugar with insulin or a sulfonylurea, and dehydration after stomach side effects, can both cloud thinking [1][2][10]. MedlinePlus describes unclear thinking as a symptom that appears when blood sugar falls further, below about 54 mg/dL [9].
Plausible but not measured: Mounjaro® decreases food intake [1], and decreased appetite affected up to 11% of people in its US placebo-controlled trials [1]. Eating far less than usual, or falling short on nutrients, could leave you feeling slow. The case report and FAERS signal point to thiamine deficiency as an extreme version of this in vulnerable people [5][6].
Indirect: if Mounjaro® is disturbing your sleep, poor sleep alone can impair focus, attention and memory [11].
Common causes that have nothing to do with the injection
Cleveland Clinic describes brain fog as a group of symptoms rather than a condition and lists frequent causes: lack of sleep, stress, anxiety or depression, hormonal changes such as menopause, autoimmune conditions, ADHD, poor nutrition, diabetes and low blood sugar, and recovery from illnesses such as COVID-19 [8]. Some medicines can also cause it [8].
For people with type 2 diabetes, both low and poorly controlled blood sugar are part of everyday life, so a fog that comes and goes may track glucose more closely than injection day. A meter or sensor reading at the time is the most direct check.
Steps that may help
Cleveland Clinic suggests improving sleep habits, eating regular nutritious meals, getting some physical activity each day, writing down important information, and taking short breaks to avoid overloading yourself [8]. It notes there is no specific treatment for brain fog and that it can last days, weeks or longer [8].
On Mounjaro®, keeping meals regular even when appetite is low supports both energy and blood sugar. If you use insulin or a sulfonylurea, the Medication Guide asks you to talk with your prescriber about how to recognise and manage low blood sugar [2]. If alcohol is a regular part of your week, tell your prescriber, since that was a key factor in the published case [6].
Do not change your Mounjaro® dose or other diabetes medicines to clear your head without talking to your prescriber.
Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Sudden confusion, a seizure, or someone who is hard to wake | Emergency services | Emergency | MedlinePlus [9][10]; Canadian monograph [4] |
| Confused, shaky or sweating while on insulin or a sulfonylurea | Treat as your plan says, then tell your prescriber; emergency care if it does not improve | Today | Medication Guide [2]; MedlinePlus [9] |
| New memory problems while eating very little, vomiting repeatedly or drinking heavily | Your clinician the same day | Today | Case report [6]; FAERS analysis [5] |
| Foggy with strong thirst, dark urine or dizziness after vomiting or diarrhea | Your prescriber | Today | Canadian monograph [4]; Medication Guide [2] |
| Fog that keeps you from ordinary tasks, makes you miss appointments or is not lifting | Your clinician | At your next appointment | Cleveland Clinic [8] |
